BioNexus Gene Lab Corp. The company is headquartered in Kuala Lumpur, Malaysia.
36 articles
BioNexus Gene Lab Corp secured an exclusive license for its CogniAI platform to support Malaysia's RM1 billion public healthcare digitization program, targeting 150 hospitals and 2,000 clinics through
BioNexus Gene Lab Corp awarded its CEO 338,709 fully vested common shares valued at $1.55 per share under the 2025 Equity Incentive Plan.
BioNexus Gene Lab Corp director Low Jook Yuen received 16,129 fully vested shares valued at $1.55 per share under the 2025 Equity Incentive Plan, increasing his direct holdings to 17,390 shares.
BioNexus Gene Lab Corp (BGLC) has released an earnings forecast detailing projected future EPS and revenue growth. The report covers market capitalization, recent price movements, and peer company com
Fidelion Diagnostics filed a Form 3 disclosing direct ownership of 392,329 shares in BioNexus Gene Lab Corp, establishing a >5% stake without recent transaction activity.
BioNexus Gene Lab Corp filed a Form 3 statement revealing Fidelion Diagnostics Pte. Ltd holds over 5% of common shares. The filing identifies Fidelion as a greater-than-5% holder with 392,329 shares a
BioNexus Gene Lab Corp filed an initial Form 3 for CFO Chong Set Fui on June 17, 2025, disclosing beneficial ownership details to the U.S. Securities and Exchange Commission.
BioNexus Gene Lab Corp (BGLC) reports a financial score of 6.04 despite a 98.93% year-over-year revenue drop to 22.84K. Net profit fell 12.79%, while several key operational metrics remain undisclosed
BioNexus Gene Lab Corp (BGLC) received a risk assessment score of 2.70 among 384 biotech companies, highlighting high volatility with a beta of 2.20 and a 78% maximum drawdown.
BioNexus Gene Lab Corp announced progress commercializing its VitaGuard™ molecular residual disease platform in Southeast Asia after technical planning visits to Chinese facilities. The company aims t
BioNexus Gene Lab Corp plans to commercialize its VitaGuard MRD liquid-biopsy platform in Southeast Asia by 2026, with test costs projected under $300. The rollout follows successful paid use in China
BioNexus Gene Lab Corp (NASDAQ:BGLC) reported Malaysia as its primary revenue contributor, generating $5.83 million last year, a decline from $7.46 million the previous year.
BioNexus Gene Lab Corp trades at $1.45, focusing on precision diagnostics and specialty chemical solutions through its subsidiaries. The company sells chemical raw materials in Southeast Asia and offe
BioNexus Gene Lab Corp (BGLC) presents earnings forecasts for future EPS and revenue growth, updated on July 26, 2026. The report includes financial health indicators and TradingKey stock scores.
BioNexus Gene Lab Corp shares traded at $1.510 with a minor decline. The report details key financial metrics including EPS, revenue forecasts, and balance sheet data for the FY2025 earnings period.
BioNexus Gene Lab Corp reported its cash flow statement, revealing an operating cash flow of -1.82M for fiscal 2025 and capital expenditures of 36.97K in the latest quarter. The data highlights the co
TradingKey analyzes BioNexus Gene Lab Corp, citing strong fundamentals and fair valuation within the Biotechnology sector. Despite recent market weakness, the company maintains significant growth pote
BioNexus Gene Lab Corp reported its shareholder structure, listing major holders like Fidelion Diagnostics and ARC Group, alongside institutional holdings data through Q1 2026.
BioNexus Gene Lab Corp (BGLC) holds a valuation score of 8.43, ranking 138th in the Biotechnology & Medical Research sector. Its P/E ratio is currently -1.02, though P/B, P/S, and P/CF data remain und
BioNexus Gene Lab Corp, a biotechnology firm specializing in chemical solutions and diagnostics, reports stock trading sideways near $1.510 with healthy fundamentals despite short-term bearish indicat
Financial analysis data for BioNexus Gene Lab Corp (NASDAQ: BGLC) details its Enterprise Value to EBITDA forward ratio on a TradingView page.
BioNexus Gene Lab Corp disclosed no dividends in the past five years and announced a 10-to-1 merger stock split scheduled for April 3, 2025.
BioNexus Gene Lab Corp has not disclosed specific revenue breakdowns by segment or region, though its current stock price and market capitalization remain available.
BioNexus Gene Lab Corp (BGLC) reports on institutional confidence metrics including stock price, market cap, and TradingKey Stock Scores. Updated June 17, 2026, the data details recent changes in inst
BioNexus Gene Lab Corp currently reports no available earnings forecasts or disclosed financial data, standing apart from the Biotechnology & Medical Research industry average of 8.13.
BioNexus Gene Lab advocates deepening Malaysia-China biotech collaboration into co-development and clinical validation, positioning Malaysia as an ASEAN execution hub. The strategy utilizes platforms
BioNexus Gene Lab urged Malaysia-China biotech co-development at the 2026 China-Malaysia Economic Cooperation Outlook Forum, proposing a precision healthcare corridor. The firm noted that a Nasdaq lis
BioNexus Gene Lab advocated for deeper Malaysia-China biotech cooperation at the 2026 Economic Cooperation Outlook Forum. CEO Sam Tan proposed positioning Malaysia as an ASEAN hub to accelerate the co
BioNexus Gene Lab Corp advocated for deeper Malaysia-China biotech collaboration at the 2026 Economic Cooperation Outlook Forum. CEO Sam Tan proposed a precision healthcare corridor to facilitate cros
BioNexus Gene Lab Corp reported Q1 2026 revenue of $22.84K, down 98.9% year-over-year, while reducing net loss per share to $0.23. The company plans to pivot toward CDMO services and VitaGuard MRD com
ChemBrief